Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Amgen | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Amgen

Reveneus up 14% in the quarter, biosimilar impacts NEUPOGEN sales

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Amgen

3Q Revenues: $5.7 billion (+14%)

3Q Earnings: $1.9 billion (+50%)

YTD Revenues: $16.1 billion (+10%)

YTD Earnings: $5.1 billion (+33%)

Comments: Growth in the quarter was primarily driven by Enbrel (+30% to $1.5 billion), Sensipar (+29% to $353 million), Neulasta (+6% to $1.3 billion), Prolia (+25% to $320 million), XGEVA (+19% to $378 million ) and Kyprolis (+46% to $137 million). NEUPOGEN sales were down 5% to $284 million impacted by Sandoz’ filgrastim biosimilar in the U.S. R&D expenses were up 11% to $1.1 billion, driven by upfront payments related to the company’s recent deal activity and increased support for launch products, offset partially by savings from transformation and process improvement efforts.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters